Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Alzheimer's Disease

Free Subscription Articles published in Brain Retrieve available abstracts of 196 articles: HTML format

Single Articles

August 2026
1. PINI L, Imbimbo BP, Corbetta M
   Reply: The disconnectome as target in Alzheimer disease: a promising framework or a premature end-point?
   Brain. 2026 Aug 6:awag263. doi: 10.1093.
   PubMed    
   
   
   
2. PALMER AM, Francis PT, Sims NR
   Fifty years of the cholinergic hypothesis: David Bowen's legacy in Alzheimer's disease.
   Brain. 2026 Aug 5:awag261. doi: 10.1093.
   PubMed    
   
   
   
3. PIRAS F, Serra L, Caltagirone C, Giove F, et al
   The disconnectome as target in Alzheimer disease: a promising framework or a premature end-point?
   Brain. 2026 Aug 5:awag262. doi: 10.1093.
   PubMed    
   
   
   
4. LONA-DURAZO F, Byrne RP, Pilon MO, Greicius MD, et al
   Sex-aware causal inference assessment of the immune system in complex neurodegenerative diseases.
   Brain. 2026;149:2716-2730.
   PubMed     Abstract available
   
   
   July 2026
5. BENBAJI M, Raveh B, Bassal L, Elias U, et al
   Alzheimer disease in the computational era: from a deterministic disease to a multifaceted disorder.
   Brain. 2026 Jul 30:awag248. doi: 10.1093.
   PubMed     Abstract available
   
   
   
6. JONES DT, Corriveau-Lecavalier N
   Reply: Interpreting early default mode network dysfunction across the Alzheimer's disease Spectrum.
   Brain. 2026 Jul 25:awag254. doi: 10.1093.
   PubMed    
   
   
   
7. SODAEI F, Vind Knudsen L
   Interpreting early default mode network dysfunction across the Alzheimer's disease spectrum.
   Brain. 2026 Jul 25:awag253. doi: 10.1093.
   PubMed    
   
   
   
8. SHEN Q, Chang H, Li J, Guo H, et al
   Photobiomodulation of immune crosstalk rescues neuroinflammation in Alzheimer's disease models.
   Brain. 2026 Jul 23:awag247. doi: 10.1093.
   PubMed     Abstract available
   
   
   
9. MARSDEN M, McLaren JE, Bevan RJ, Penn-Ripley D, et al
   Cytomegalovirus-induced T cell responses accelerate Alzheimer's disease progression in mice.
   Brain. 2026 Jul 13:awag043. doi: 10.1093.
   PubMed     Abstract available
   
   
   
10. BANERJEE G, van Veluw SJ
    Untangling the web of APOE, cerebral amyloid angiopathy and Alzheimer's disease.
    Brain. 2026 Jul 10:awag243. doi: 10.1093.
    PubMed    
    
    
    
11. PELKMANS W, Bikou V, Salvado G
    Timing the Alzheimer's disease pathological cascade.
    Brain. 2026 Jul 8:awag240. doi: 10.1093.
    PubMed    
    
    
    
12. LIU N, Yang Y, Kritsilis M, Swanberg KM, et al
    Early glymphatic failure in AppNL-F knock-in mice is linked to parenchymal border macrophages loss.
    Brain. 2026;149:2422-2437.
    PubMed     Abstract available
    
    
    
13. TUNG TH, Babu S, Tang X, Sciutto AL, et al
    Fus-depleted oligodendrocytes reduce neuronal damage and Alzheimer's disease progression in the AppNL-G-F mouse.
    Brain. 2026 Jul 6:awag234. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2026
14. BHARDWAJ A, Benveniste H
    Amyloid-beta-laden CSF turns guardian macrophages into collateral damage in Alzheimer's disease.
    Brain. 2026 Jun 5:awag197. doi: 10.1093.
    PubMed    
    
    
    
15. WISCH JK, Jiao Z, Kennedy JT, Cohen AD, et al
    Imaging and plasma biomarkers for pathological accumulation in Down syndrome.
    Brain. 2026;149:1944-1957.
    PubMed     Abstract available
    
    
    May 2026
16. GAWOR K, Statz K, Schaeverbeke J, Thal DR, et al
    Alzheimer's disease subtyping approaches and the role of co-pathologies.
    Brain. 2026 May 4:awag157. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2026
17. TOSUN D
    APOE shifts the tipping point: addressing pathological heterogeneity in Alzheimer's disease trials.
    Brain. 2026 Apr 29:awag151. doi: 10.1093.
    PubMed    
    
    
    
18. CORRIVEAU-LECAVALIER N, Dicks E, Martin PR, Wiste HJ, et al
    Default mode network failure across the Alzheimer's disease spectrum.
    Brain. 2026 Apr 22:awag146. doi: 10.1093.
    PubMed     Abstract available
    
    
    
19. BENINA N, Buitrago L, De Simone FI, Radwan RR, et al
    Plasma pTau 217/beta-amyloid 1-42 ratio for enhanced accuracy and reduced uncertainty in detecting amyloid pathology.
    Brain. 2026;149:1168-1181.
    PubMed     Abstract available
    
    
    
20. WATANABE H, Whitwell JL, Bhaskaran JG, Lowe VJ, et al
    Imposter in the brain: aetiological, clinical and neuroimaging characteristics of Capgras syndrome.
    Brain. 2026;149:1224-1238.
    PubMed     Abstract available
    
    
    March 2026
21. BARRANTES FJ
    Synapse-associated neuropathological markers in Alzheimer disease.
    Brain. 2026 Mar 30:awag117. doi: 10.1093.
    PubMed     Abstract available
    
    
    
22. YOUNG CB, Sheng J, Winer JR, Cody K, et al
    Longitudinal trajectories of divergent cortical tau patterns in preclinical Alzheimer's disease.
    Brain. 2026 Mar 26:awag113. doi: 10.1093.
    PubMed     Abstract available
    
    
    
23. WEISE CM, Abu-Rumeileh S, Otto M
    From 'senile dementia' to non-vascular Alzheimer's synucleinopathy: the evolution of dementia classification.
    Brain. 2026 Mar 16:awag103. doi: 10.1093.
    PubMed    
    
    
    
24. LEE J, Cho Y, Choi BY, Kim HK, et al
    HDAC6 regulates BACE1 stability and NLRP3 inflammasome activation in Alzheimer's disease.
    Brain. 2026 Mar 6:awag089. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2026
25. KALARIA RN
    The rise and rise of vascular dysfunction in Alzheimer's disease.
    Brain. 2026 Feb 25:awag076. doi: 10.1093.
    PubMed    
    
    
    
26. LAGARTOS-DONATE MJ, Escobar-Doncel B, Zhang SQ, Pan JP, et al
    Loss of REST associated with Alzheimer's disease pathology is ameliorated by NAD.
    Brain. 2026 Feb 19:awaf261. doi: 10.1093.
    PubMed     Abstract available
    
    
    January 2026
27. MEHTA RI, Wang T, Leurgans SE, Bennett DA, et al
    Cerebral amyloid angiopathy and Alzheimer's and related pathologies across APOE genotypes.
    Brain. 2026 Jan 22:awag025. doi: 10.1093.
    PubMed     Abstract available
    
    
    
28. TRUDEL L, Therriault J, Macedo AC, Hosseini SA, et al
    Clinical-biological Alzheimer's disease stage concordance: insights from cohorts and autopsy data.
    Brain. 2026 Jan 20:awag018. doi: 10.1093.
    PubMed     Abstract available
    
    
    
29. YANG T, Zhang D, Huang H, Liu F, et al
    Astrocytic mGluR5-dependent calcium hyperactivity promotes amyloid-beta pathology and cognitive impairment.
    Brain. 2026;149:134-149.
    PubMed     Abstract available
    
    
    December 2025
30. STEWARD A, Dewenter A, Hirsch F, Roemer-Cassiano SN, et al
    ApoE4 lowers the ptau217 threshold for tau aggregation and spread in an allele dose-dependent manner.
    Brain. 2025 Dec 18:awaf463. doi: 10.1093.
    PubMed     Abstract available
    
    
    
31. ZU J, Li C, Cui M, Liu X, et al
    Pioglitazone attenuates complement-mediated microglial synaptic engulfment in an Alzheimer's disease model.
    Brain. 2025 Dec 15:awaf462. doi: 10.1093.
    PubMed     Abstract available
    
    
    November 2025
32. PINI L, Allali G, Imbimbo BP, Germani M, et al
    Brain connectivity as a new target for Alzheimer's disease therapy?
    Brain. 2025 Nov 28:awaf404. doi: 10.1093.
    PubMed     Abstract available
    
    
    
33. KIM B, Yuk M, Park M, Ryu H, et al
    CRISPR editing of miR-33 restores ApoE lipidation and amyloid-beta metabolism in ApoE4 sporadic Alzheimer's disease.
    Brain. 2025 Nov 25:awaf244. doi: 10.1093.
    PubMed     Abstract available
    
    
    
34. ZAMMIT MD, Bruzzone H, Cody KA, Morse J, et al
    The tau biomarker cascade is condensed in Down syndrome compared to sporadic Alzheimer's disease.
    Brain. 2025 Nov 15:awaf428. doi: 10.1093.
    PubMed     Abstract available
    
    
    
35. LUAN Y, Huang Q, Wang J, Guan Y, et al
    Synaptic density and tau pathology in Alzheimer's disease: a dual role in susceptibility and degeneration.
    Brain. 2025 Nov 13:awaf425. doi: 10.1093.
    PubMed     Abstract available
    
    
    
36. LI LL, Wang RZ, Wang Z, Hu H, et al
    Safety and short-term outcomes of lecanemab for Alzheimer's disease in China: a multicentre study.
    Brain. 2025 Nov 11:awaf427. doi: 10.1093.
    PubMed     Abstract available
    
    
    
37. WESSELING A, Calandri IL, Bouwman MMA, Reijner N, et al
    Amygdalar and hippocampal volume loss in limbic-predominant age-related TDP-43 encephalopathy.
    Brain. 2025;148:3913-3923.
    PubMed     Abstract available
    
    
    
38. RAKET LL, Pichet Binette A, Mattsson-Carlgren N, Janelidze S, et al
    Estimating the time course of biomarker changes in Alzheimer's disease.
    Brain. 2025 Nov 3:awaf413. doi: 10.1093.
    PubMed     Abstract available
    
    
    October 2025
39. NEITZEL J
    White matter changes in Alzheimer's disease: contributor, consequence or co-pathology?
    Brain. 2025 Oct 30:awaf415. doi: 10.1093.
    PubMed    
    
    
    
40. ASBY DJ, Fisher RA, Jackson J, Love S, et al
    Post-mortem evidence of pathogenic angiogenesis and abnormal vascular function in early Alzheimer's disease.
    Brain. 2025 Oct 22:awaf394. doi: 10.1093.
    PubMed     Abstract available
    
    
    
41. MORRIS LA, Suzuki H, Lee S, Jin Z, et al
    Apathy, effort-based decisions and brain integrity in Alzheimer's and Parkinson's diseases.
    Brain. 2025 Oct 17:awaf393. doi: 10.1093.
    PubMed     Abstract available
    
    
    
42. RUIZ-REIG N, Virosztek M, Chehade G, Suelves N, et al
    KIF2A downregulation links amyloid-beta to Tau phosphorylation in Alzheimer's disease.
    Brain. 2025 Oct 10:awaf382. doi: 10.1093.
    PubMed     Abstract available
    
    
    
43. ALEXANDERSEN CG, Bassett DS, Goriely A, Chaggar P, et al
    Neuronal activity and amyloid-beta promote tau seeding in the entorhinal cortex in Alzheimer's disease.
    Brain. 2025 Oct 7:awaf374. doi: 10.1093.
    PubMed     Abstract available
    
    
    
44. KARLSSON L, Janelidze S, Barthelemy NR, Horie K, et al
    Reference proteins to improve Core 1 and Core 2 Alzheimer's disease CSF and plasma biomarkers.
    Brain. 2025 Oct 6:awaf375. doi: 10.1093.
    PubMed     Abstract available
    
    
    
45. VERBERK IMW, van Harten AC, van der Flier WM
    Opposing views or like-minded? International Working Group and Alzheimer's Association criteria.
    Brain. 2025 Oct 1:awaf366. doi: 10.1093.
    PubMed    
    
    
    September 2025
46. JOHNSON DR, Wiste HJ, Lowe V, Schwarz CG, et al
    Staging Alzheimer's disease through amyloid and tau PET.
    Brain. 2025 Sep 19:awaf346. doi: 10.1093.
    PubMed     Abstract available
    
    
    
47. PESCOLLER J, Dewenter A, Dehsarvi A, Steward A, et al
    Cortical tau deposition promotes atrophy in connected white matter regions in Alzheimer's disease.
    Brain. 2025 Sep 12:awaf339. doi: 10.1093.
    PubMed     Abstract available
    
    
    
48. YU L, Du L, Wang T, Barnes LL, et al
    Neuropathologic correlates of distinct plasma biomarker profiles in community-living older adults.
    Brain. 2025;148:3340-3349.
    PubMed     Abstract available
    
    
    August 2025
49. DE BRUIN H, Groot C, Barthel H, Bischof GN, et al
    Connectivity as a universal predictor of tau progression in atypical Alzheimer's disease.
    Brain. 2025 Aug 14:awaf279. doi: 10.1093.
    PubMed     Abstract available
    
    
    
50. SKELLY D, Attfield KE, Fugger L
    T cells turn in Alzheimer's disease.
    Brain. 2025 Aug 14:awaf288. doi: 10.1093.
    PubMed    
    
    
    
51. ESPAY AJ, Ezzat K, Kepp KP, Daly T, et al
    Restoring amyloid-beta42 and gamma-secretase function in Alzheimer's disease.
    Brain. 2025 Aug 8:awaf294. doi: 10.1093.
    PubMed     Abstract available
    
    
    
52. M'BRA PEH, Hamilton LK, Moquin-Beaudry G, Mangahas CL, et al
    Medium-chain triglycerides improve cognition and systemic metabolism in mouse models of Alzheimer's disease.
    Brain. 2025 Aug 6:awaf267. doi: 10.1093.
    PubMed     Abstract available
    
    
    
53. BERSON E, Perna A, Bukhari S, Kim Y, et al
    Deep learning-based cell type profiles reveal signatures of Alzheimer's disease resilience and resistance.
    Brain. 2025 Aug 5:awaf285. doi: 10.1093.
    PubMed     Abstract available
    
    
    
54. SAADMAAN G, Dalmasso MC, Maria M, Lehtisalo J, et al
    Alzheimer and cardiovascular genetic scores and cognition: the FINGER randomized controlled trial.
    Brain. 2025 Aug 1:awaf277. doi: 10.1093.
    PubMed     Abstract available
    
    
    
55. ZUO M, Chang L, Neale N, Maameri L, et al
    The relationship between kidney health and neurodegenerative diseases.
    Brain. 2025;148:2616-2630.
    PubMed     Abstract available
    
    
    July 2025
56. HAMID M, Detroja TS, Tripathy SJ, Menon V, et al
    Sleep, pericyte subtypes and cognitive decline in adults with and without Alzheimer's disease.
    Brain. 2025 Jul 14:awaf161. doi: 10.1093.
    PubMed     Abstract available
    
    
    
57. ANAND C, Abdelnour F, Sipes B, Ma D, et al
    Selective vulnerability and resilience to Alzheimer's disease tauopathy as a function of genes and the connectome.
    Brain. 2025 Jul 9:awaf179. doi: 10.1093.
    PubMed     Abstract available
    
    
    
58. WEIL RS
    Seeing the trees in the wood: the importance of co-pathologies in Alzheimer's disease and dementia with Lewy bodies.
    Brain. 2025;148:2233-2234.
    PubMed    
    
    
    
59. WOODWORTH DC, Lou JJ, Yong WH, Head E, et al
    Common neuropathologic change drivers of hippocampal sclerosis of ageing.
    Brain. 2025;148:2400-2411.
    PubMed     Abstract available
    
    
    
60. CHEN J, Li Q, Ji B, Zhang K, et al
    Single-nucleus transcriptome atlas of the basal forebrain reveals diverse ageing-related pathways.
    Brain. 2025;148:2493-2508.
    PubMed     Abstract available
    
    
    
61. SILVA-RODRIGUEZ J, Labrador-Espinosa MA, Zhang L, Castro-Labrador S, et al
    The effect of Lewy body (co-)pathology on the clinical and imaging phenotype of amnestic patients.
    Brain. 2025;148:2441-2452.
    PubMed     Abstract available
    
    
    
62. ZAWAR I, Luniewski A, Gundlapalli R, Manning C, et al
    The association of seizure control with neuropathology in dementia.
    Brain. 2025;148:2469-2480.
    PubMed     Abstract available
    
    
    
63. CICOGNOLA C, Salvado G, Smith R, Palmqvist S, et al
    APOE4 impact on soluble and insoluble tau pathology is mostly influenced by amyloid-beta.
    Brain. 2025;148:2373-2383.
    PubMed     Abstract available
    
    
    
64. GRAHAM NSN, Zimmerman KA, Hain J, Rooney E, et al
    Biomarker evidence of neurodegeneration in mid-life former rugby players.
    Brain. 2025 Jul 3:awaf152. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2025
65. SCARMEAS N, Noriega De La Colina A
    The duality of disease: the Alzheimer's disease dilemma through the lens of nosos and asthenia.
    Brain. 2025 Jun 26:awaf239. doi: 10.1093.
    PubMed    
    
    
    
66. JIANG S, Srikanth M, Serpe R, Yavari S, et al
    Early proteasome downregulation and dysfunction drive proteostasis failure in Alzheimer's disease.
    Brain. 2025 Jun 9:awaf222. doi: 10.1093.
    PubMed     Abstract available
    
    
    
67. VELLONE D, Leon R, Goodarzi Z, Forkert ND, et al
    Mild behavioural impairment-apathy and core Alzheimer's disease cerebrospinal fluid biomarkers.
    Brain. 2025 Jun 2:awaf194. doi: 10.1093.
    PubMed     Abstract available
    
    
    May 2025
68. ABDEL-HALEEM AM, Casavant E, Toth B, Teng E, et al
    CSF proteomics of semorinemab Alzheimer's disease trials identifies cell-type specific signatures.
    Brain. 2025 May 28:awaf200. doi: 10.1093.
    PubMed     Abstract available
    
    
    
69. WISSE LEM, La Joie R
    Medial temporal lobe structural changes when Down syndrome and Alzheimer's disease collide.
    Brain. 2025 May 14:awaf176. doi: 10.1093.
    PubMed    
    
    
    
70. RICKENBACH C, Mallone A, Hausle L, Frei L, et al
    Altered T-cell reactivity in the early stages of Alzheimer's disease.
    Brain. 2025 May 5:awaf167. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2025
71. POMARA N, Imbimbo BP
    Making a diagnosis of Alzheimer's disease in asymptomatic individuals with positive biomarkers.
    Brain. 2025 Apr 28:awaf162. doi: 10.1093.
    PubMed    
    
    
    
72. SHARIF SF, Guan DX, Bodnar T, Joseph JT, et al
    Neuropsychiatric symptoms and progression to pathologically confirmed Alzheimer's disease.
    Brain. 2025 Apr 25:awaf156. doi: 10.1093.
    PubMed     Abstract available
    
    
    
73. ABANTO JT, Dwivedi AK, Imbimbo BP, Espay AJ, et al
    CSF amyloid-beta40 levels are not associated with efficacy outcomes in Alzheimer's disease trials.
    Brain. 2025 Apr 19:awaf143. doi: 10.1093.
    PubMed    
    
    
    
74. BUEHNER BJ, Morcillo-Nieto AO, Zsadanyi SE, Rozalem Aranha M, et al
    Medial temporal lobe atrophy in Down syndrome along the Alzheimer's disease continuum.
    Brain. 2025 Apr 17:awaf133. doi: 10.1093.
    PubMed     Abstract available
    
    
    
75. LU K, Baker J, Nicholas JM, Street RE, et al
    Associations between accelerated forgetting, amyloid deposition and brain atrophy in older adults.
    Brain. 2025;148:1302-1315.
    PubMed     Abstract available
    
    
    March 2025
76. ZITSER J, Forner S, Wong K, Chengshi J, et al
    Neuropsychiatric symptoms in sporadic Creutzfeldt-Jakob disease.
    Brain. 2025 Mar 28:awaf077. doi: 10.1093.
    PubMed     Abstract available
    
    
    
77. PHILLIPS JM, Dumitrescu LC, Archer DB, Regelson AN, et al
    Novel modelling approaches to elucidate the genetic architecture of resilience to Alzheimer's disease.
    Brain. 2025 Mar 20:awaf106. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2025
78. 
    Correction to: Plasma p-tau217 in Alzheimer's disease: Lumipulse and ALZpath SIMOA head-to-head comparison.
    Brain. 2025 Feb 6:awaf034. doi: 10.1093.
    PubMed    
    
    
    
79. LIU H, Marsh TW, Shi X, Renton AE, et al
    The landscape of autosomal-dominant Alzheimer's disease: global distribution and age of onset.
    Brain. 2025 Feb 4:awaf038. doi: 10.1093.
    PubMed     Abstract available
    
    
    
80. HUSAIN M
    Listening into hippocampal hyperexcitability in Alzheimer's disease.
    Brain. 2025;148:347-348.
    PubMed    
    
    
    
81. WARMENHOVEN N, Salvado G, Janelidze S, Mattsson-Carlgren N, et al
    A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests.
    Brain. 2025;148:416-431.
    PubMed     Abstract available
    
    
    January 2025
82. FERNANDEZ ARIAS J, Brum WS, Salvado G, Therriault J, et al
    Plasma phosphorylated tau217 strongly associates with memory deficits in the Alzheimer's disease spectrum.
    Brain. 2025 Jan 29:awaf033. doi: 10.1093.
    PubMed     Abstract available
    
    
    
83. CHAUVEAU L, Landeau B, Dautricourt S, Turpin AL, et al
    Anterior-temporal network hyperconnectivity is key to Alzheimer's disease: from ageing to dementia.
    Brain. 2025 Jan 15:awaf008. doi: 10.1093.
    PubMed     Abstract available
    
    
    
84. GRAHAM AC, Bellou E, Harwood JC, Yaman U, et al
    Human longevity and Alzheimer's disease variants act via microglia and oligodendrocyte gene networks.
    Brain. 2025 Jan 9:awae339. doi: 10.1093.
    PubMed     Abstract available
    
    
    
85. VAN DER FLIER WM, Heneka MT
    Zooming in on brain inflammation in Alzheimer's disease.
    Brain. 2025;148:1-2.
    PubMed    
    
    
    
86. TIAN F, Wang Y, Qian ZM, Ran S, et al
    Plasma metabolomic signature of healthy lifestyle, structural brain reserve and risk of dementia.
    Brain. 2025;148:143-153.
    PubMed     Abstract available
    
    
    December 2024
87. PILOTTO A, Quaresima V, Trasciatti C, Tolassi C, et al
    Plasma p-tau217 in Alzheimer's disease: Lumipulse and ALZpath SIMOA head-to-head comparison.
    Brain. 2024 Dec 16:awae368. doi: 10.1093.
    PubMed     Abstract available
    
    
    
88. WANG D, Honnorat N, Toledo JB, Li K, et al
    Deep learning reveals pathology-confirmed neuroimaging signatures in Alzheimer's, vascular and Lewy body dementias.
    Brain. 2024 Dec 9:awae388. doi: 10.1093.
    PubMed     Abstract available
    
    
    
89. LEE SH, Bae EJ, Perez-Acuna D, Jung MK, et al
    Amyloid-beta-activated microglia can induce compound proteinopathies.
    Brain. 2024;147:4105-4120.
    PubMed     Abstract available
    
    
    November 2024
90. DUONG MT, Das SR, Khandelwal P, Lyu X, et al
    Hypometabolic mismatch with atrophy and tau pathology in mixed Alzheimer and Lewy body disease.
    Brain. 2024 Nov 22:awae352. doi: 10.1093.
    PubMed     Abstract available
    
    
    
91. KOCH G, Altomare D, Benussi A, Brechet L, et al
    The emerging field of non-invasive brain stimulation in Alzheimer's disease.
    Brain. 2024 Nov 20:awae292. doi: 10.1093.
    PubMed     Abstract available
    
    
    
92. COLLOBY SJ, McAleese KE, Walker L, Erskine D, et al
    Patterns of tau, amyloid and synuclein pathology in ageing, Alzheimer's disease and synucleinopathies.
    Brain. 2024 Nov 12:awae372. doi: 10.1093.
    PubMed     Abstract available
    
    
    
93. PELKMANS W, Gispert JD
    Astroglial reactivity is a key modulator of Alzheimer's disease pathological progression.
    Brain. 2024 Nov 8:awae354. doi: 10.1093.
    PubMed    
    
    
    
94. MACMULLEN C, Sharma N, Davis RL
    Mitochondrial dynamics and bioenergetics in Alzheimer's induced pluripotent stem cell-derived neurons.
    Brain. 2024 Nov 8:awae364. doi: 10.1093.
    PubMed     Abstract available
    
    
    
95. DALY T, Imbimbo BP
    Metformin may reduce Alzheimer's disease risk by increasing soluble amyloid-beta42 levels.
    Brain. 2024 Nov 8:awae367. doi: 10.1093.
    PubMed    
    
    
    
96. WELIKOVITCH LA, Mate de Gerando A, Khasnavis A, Bhavsar H, et al
    Tau, synapse loss and gliosis progress in an Alzheimer's mouse model after amyloid-beta immunotherapy.
    Brain. 2024 Nov 6:awae345. doi: 10.1093.
    PubMed     Abstract available
    
    
    
97. SAKATO Y, Shima A, Terada Y, Takeda K, et al
    Delineating three distinct spatiotemporal patterns of brain atrophy in Parkinson's disease.
    Brain. 2024;147:3702-3713.
    PubMed     Abstract available
    
    
    
98. BENJAMIN-ZUKERMAN T, Shimon G, Gaine ME, Dakwar A, et al
    A mutation in the PRKAR1B gene drives pathological mechanisms of neurodegeneration across species.
    Brain. 2024;147:3890-3905.
    PubMed     Abstract available
    
    
    October 2024
99. KOVACS GG, Katsumata Y, Wu X, Aung KZ, et al
    Amyloid-beta predominant Alzheimer's disease neuropathologic change.
    Brain. 2024 Oct 17:awae325. doi: 10.1093.
    PubMed     Abstract available
    
    
    
100. KATSUMI Y, Howe IA, Eckbo R, Wong B, et al
     Default mode network tau predicts future clinical decline in atypical early Alzheimer's disease.
     Brain. 2024 Oct 16:awae327. doi: 10.1093.
     PubMed     Abstract available
     
     
     
101. AGRAWAL S, Yu L, Leurgans SE, Kapasi A, et al
     Grey matter ageing-related tau astrogliopathy: associations with brain pathologies and cognitive decline.
     Brain. 2024;147:3501-3512.
     PubMed     Abstract available
     
     
     
102. REUS LM, Jansen IE, Tijms BM, Visser PJ, et al
     Connecting dementia risk loci to the CSF proteome identifies pathophysiological leads for dementia.
     Brain. 2024;147:3522-3533.
     PubMed     Abstract available
     
     
     September 2024
103. ABANTO J, Dwivedi AK, Imbimbo BP, Espay AJ, et al
     Increases in amyloid-beta42 slow cognitive and clinical decline in Alzheimer's disease trials.
     Brain. 2024 Sep 11:awae216. doi: 10.1093.
     PubMed     Abstract available
     
     
     August 2024
104. ZELEK WM, Bevan RJ, Nimmo J, Dewilde M, et al
     Brain-penetrant complement inhibition mitigates neurodegeneration in an Alzheimer's disease mouse model.
     Brain. 2024 Aug 31:awae278. doi: 10.1093.
     PubMed     Abstract available
     
     
     
105. SHAHIDEHPOUR RK, Nelson PT, Katsumata Y, Bachstetter AD, et al
     Exploring the link between dystrophic microglia and the spread of Alzheimer's neuropathology.
     Brain. 2024 Aug 5:awae258. doi: 10.1093.
     PubMed     Abstract available
     
     
     
106. GOMEZ-MURCIA V, Launay A, Carvalho K, Burgard A, et al
     Neuronal A2A receptor exacerbates synapse loss and memory deficits in APP/PS1 mice.
     Brain. 2024;147:2691-2705.
     PubMed     Abstract available
     
     
     July 2024
107. YANG Y, Chen H, Huang S, Chen H, et al
     BOK-engaged mitophagy alleviates neuropathology in Alzheimer's disease.
     Brain. 2024 Jul 25:awae241. doi: 10.1093.
     PubMed     Abstract available
     
     
     
108. MATTSSON-CARLGREN N
     Disentangling genetic risks for development and progression of Alzheimer's disease.
     Brain. 2024 Jul 18:awae237. doi: 10.1093.
     PubMed    
     
     
     
109. RAMANAN S, Akarca D, Henderson SK, Rouse MA, et al
     The graded multidimensional geometry of phenotypic variation and progression in neurodegenerative syndromes.
     Brain. 2024 Jul 17:awae233. doi: 10.1093.
     PubMed     Abstract available
     
     
     
110. APPLETON J, Finn Q, Zanotti-Fregonara P, Yu M, et al
     Brain inflammation co-localizes highly with tau in mild cognitive impairment due to early-onset Alzheimer's disease.
     Brain. 2024 Jul 16:awae234. doi: 10.1093.
     PubMed     Abstract available
     
     
     
111. CAI H, Zhao T, Pang Y, Fu X, et al
     Systemic inflammatory markers in ageing, Alzheimer's disease and other dementias.
     Brain. 2024 Jul 15:awae230. doi: 10.1093.
     PubMed     Abstract available
     
     
     
112. BARBA L, Abu-Rumeileh S, Barthel H, Massa F, et al
     Clinical and diagnostic implications of Alzheimer's disease copathology in Lewy body disease.
     Brain. 2024 Jul 11:awae203. doi: 10.1093.
     PubMed     Abstract available
     
     
     
113. DEVULDER A, Vanderlinden G, Van Langenhoven L, Testelmans D, et al
     Epileptic activity on foramen ovale electrodes is associated with sleep and tau pathology in Alzheimer's disease.
     Brain. 2024 Jul 11:awae231. doi: 10.1093.
     PubMed     Abstract available
     
     
     
114. HUSAIN M
     The heterogeneity of Alzheimer's disease.
     Brain. 2024;147:2259-2260.
     PubMed    
     
     
     
115. OKKELS N, Grothe MJ, Taylor JP, Hasselbalch SG, et al
     Cholinergic changes in Lewy body disease: implications for presentation, progression and subtypes.
     Brain. 2024;147:2308-2324.
     PubMed     Abstract available
     
     
     
116. NILSSON J, Pichet Binette A, Palmqvist S, Brum WS, et al
     Cerebrospinal fluid biomarker panel for synaptic dysfunction in a broad spectrum of neurodegenerative diseases.
     Brain. 2024;147:2414-2427.
     PubMed     Abstract available
     
     
     June 2024
117. PERETTI DE, Boccalini C, Ribaldi F, Scheffler M, et al
     Association of glial fibrillary acid protein, Alzheimer's disease pathology and cognitive decline.
     Brain. 2024 Jun 28:awae211. doi: 10.1093.
     PubMed     Abstract available
     
     
     
118. 
     Correction to: Microbiota from Alzheimer's patients induce deficits in cognition and hippocampal neurogenesis.
     Brain. 2024 Jun 28:awae208. doi: 10.1093.
     PubMed    
     
     
     
119. OLNEY KC, Rabichow BE, Wojtas AM, DeTure M, et al
     Distinct transcriptional alterations distinguish Lewy body disease from Alzheimer's disease.
     Brain. 2024 Jun 25:awae202. doi: 10.1093.
     PubMed     Abstract available
     
     
     
120. BALLERINI A, Biagioli N, Carbone C, Chiari A, et al
     Late-onset temporal lobe epilepsy: insights from brain atrophy and Alzheimer's disease biomarkers.
     Brain. 2024 Jun 25:awae207. doi: 10.1093.
     PubMed     Abstract available
     
     
     
121. COOMANS EM, Ossenkoppele R
     The implications of amyloid-beta pathology: only time will tell.
     Brain. 2024;147:1934-1936.
     PubMed    
     
     
     May 2024
122. ALTMANN A, Aksman LM, Oxtoby NP, Young A, et al
     Towards cascading genetic risk in Alzheimer's disease.
     Brain. 2024 May 31:awae176. doi: 10.1093.
     PubMed     Abstract available
     
     
     
123. CHEN F, Zhao J, Meng F, He F, et al
     The vascular contribution of apolipoprotein E to Alzheimer's disease.
     Brain. 2024 May 15:awae156. doi: 10.1093.
     PubMed     Abstract available
     
     
     
124. SOCH J, Richter A, Kizilirmak JM, Schutze H, et al
     Single-value brain activity scores reflect both severity and risk across the Alzheimer's continuum.
     Brain. 2024 May 14:awae149. doi: 10.1093.
     PubMed     Abstract available
     
     
     
125. BLUM D, Levi S
     Targeting excitatory:inhibitory network imbalance in Alzheimer's disease.
     Brain. 2024 May 13:awae146. doi: 10.1093.
     PubMed    
     
     
     
126. SANCHEZ-JUAN P, Valeriano-Lorenzo E, Ruiz-Gonzalez A, Pastor AB, et al
     Serum GFAP levels correlate with astrocyte reactivity, post-mortem brain atrophy and neurofibrillary tangles.
     Brain. 2024;147:1667-1679.
     PubMed     Abstract available
     
     
     
127. DING F, Sun Q, Long C, Rasmussen RN, et al
     Dysregulation of extracellular potassium distinguishes healthy ageing from neurodegeneration.
     Brain. 2024;147:1726-1739.
     PubMed     Abstract available
     
     
     April 2024
128. CODY KA, Langhough RE, Zammit MD, Clark L, et al
     Characterizing brain tau and cognitive decline along the amyloid timeline in Alzheimer's disease.
     Brain. 2024 Apr 26:awae116. doi: 10.1093.
     PubMed     Abstract available
     
     
     
129. BARBOUR AJ, Gourmaud S, Lancaster E, Li X, et al
     Seizures exacerbate excitatory: inhibitory imbalance in Alzheimer's disease and 5XFAD mice.
     Brain. 2024 Apr 25:awae126. doi: 10.1093.
     PubMed     Abstract available
     
     
     
130. BAUMEISTER H, Vogel JW, Insel PS, Kleineidam L, et al
     A generalizable data-driven model of atrophy heterogeneity and progression in memory clinic settings.
     Brain. 2024 Apr 24:awae118. doi: 10.1093.
     PubMed     Abstract available
     
     
     
131. LIMBERGER C, Zimmer ER
     Blood GFAP reflects astrocyte reactivity to Alzheimer's pathology in post-mortem brain tissue.
     Brain. 2024 Apr 18:awae104. doi: 10.1093.
     PubMed    
     
     
     
132. 
     Correction to: Disrupted daily activity/rest cycles in relation to daily cortisol rhythms of home-dwelling patients with early Alzheimer's dementia.
     Brain. 2024 Apr 10:awae103. doi: 10.1093.
     PubMed    
     
     
     
133. WANG YT, Therriault J, Servaes S, Tissot C, et al
     Sex-specific modulation of amyloid-beta on tau phosphorylation underlies faster tangle accumulation in females.
     Brain. 2024;147:1497-1510.
     PubMed     Abstract available
     
     
     
134. TANAKA H, Martinez-Valbuena I, Forrest SL, Couto B, et al
     Distinct involvement of the cranial and spinal nerves in progressive supranuclear palsy.
     Brain. 2024;147:1399-1411.
     PubMed     Abstract available
     
     
     
135. CORRIVEAU-LECAVALIER N, Barnard LR, Botha H, Graff-Radford J, et al
     Uncovering the distinct macro-scale anatomy of dysexecutive and behavioural degenerative diseases.
     Brain. 2024;147:1483-1496.
     PubMed     Abstract available
     
     
     March 2024
136. HUNG C, Fertan E, Livesey FJ, Klenerman D, et al
     APP antisense oligonucleotides reduce Abeta aggregation and rescue endolysosomal dysfunction in Alzheimer's disease.
     Brain. 2024 Mar 25:awae092. doi: 10.1093.
     PubMed     Abstract available
     
     
     
137. RODRIGUEZ-RODRIGUEZ P, Arroyo-Garcia LE, Tsagkogianni C, Li L, et al
     A cell autonomous regulator of neuronal excitability modulates tau in Alzheimer's disease vulnerable neurons.
     Brain. 2024 Mar 11:awae051. doi: 10.1093.
     PubMed     Abstract available
     
     
     
138. RODRIGUEZ-VIEITEZ E, Vannini P, Montal V, Graff C, et al
     Cortical microstructural imaging from diffusion MRI: towards sensitive biomarkers for clinical trials.
     Brain. 2024;147:746-748.
     PubMed    
     
     
     
139. DE MEYER S, Blujdea ER, Schaeverbeke J, Reinartz M, et al
     Longitudinal associations of serum biomarkers with early cognitive, amyloid and grey matter changes.
     Brain. 2024;147:936-948.
     PubMed     Abstract available
     
     
     February 2024
140. YANG HS, Yau WW, Carlyle BC, Trombetta BA, et al
     Plasma VEGFA and PGF impact longitudinal tau and cognition in preclinical Alzheimer's disease.
     Brain. 2024 Feb 5:awae034. doi: 10.1093.
     PubMed     Abstract available
     
     
     
141. AHMED H, Wang Y, Griffiths WJ, Levey AI, et al
     Brain cholesterol and Alzheimer's disease: challenges and opportunities in probe and drug development.
     Brain. 2024 Feb 1:awae028. doi: 10.1093.
     PubMed     Abstract available
     
     
     
142. ALBERT-GASCO H, Smith HL, Alvarez-Castelao B, Swinden D, et al
     Trazodone rescues dysregulated synaptic and mitochondrial nascent proteomes in prion neurodegeneration.
     Brain. 2024;147:649-664.
     PubMed     Abstract available
     
     
     January 2024
143. KUMAR M, Quittot N, Dujardin S, Schlaffner CN, et al
     Alzheimer proteopathic tau seeds are biochemically a forme fruste of mature paired helical filaments.
     Brain. 2024 Jan 18:awad378. doi: 10.1093.
     PubMed     Abstract available
     
     
     
144. KIIANITSA K, Lukes ME, Hayes BJ, Brutman J, et al
     TREM2 variants that cause early dementia and increase Alzheimer's disease risk affect gene splicing.
     Brain. 2024 Jan 16:awae014. doi: 10.1093.
     PubMed     Abstract available
     
     
     
145. HAN Y, Chen K, Zhang B, Yu H, et al
     Maf1 loss regulates spinogenesis and attenuates cognitive impairment in Alzheimer's disease.
     Brain. 2024 Jan 16:awae015. doi: 10.1093.
     PubMed     Abstract available
     
     
     
146. QIN C, Chen M, Dong MH, Yang S, et al
     Soluble TREM2 triggers microglial dysfunction in neuromyelitis optica spectrum disorders.
     Brain. 2024;147:163-176.
     PubMed     Abstract available
     
     
     December 2023
147. SAMANTA S, Akhter F, Roy A, Chen D, et al
     New cyclophilin D inhibitor rescues mitochondrial and cognitive function in Alzheimer's disease.
     Brain. 2023 Dec 26:awad432. doi: 10.1093.
     PubMed     Abstract available
     
     
     
148. SPOTORNO N, Strandberg O, Stomrud E, Janelidze S, et al
     Diffusion MRI tracks cortical microstructural changes during the early stages of Alzheimer's disease.
     Brain. 2023 Dec 21:awad428. doi: 10.1093.
     PubMed     Abstract available
     
     
     
149. STOUFFER KM, Grande X, Duezel E, Johansson M, et al
     Amidst an amygdala renaissance in Alzheimer's disease.
     Brain. 2023 Dec 18:awad411. doi: 10.1093.
     PubMed     Abstract available
     
     
     
150. YUYAMA K, Sun H, Fujii R, Hemmi I, et al
     Extracellular vesicle proteome unveils cathepsin B connection to Alzheimer's disease pathogenesis.
     Brain. 2023 Dec 10:awad361. doi: 10.1093.
     PubMed     Abstract available
     
     
     
151. TARUTANI A, Kametani F, Tahira M, Saito Y, et al
     Distinct tau folds initiate templated seeding and alter the post-translational modification profile.
     Brain. 2023;146:4988-4999.
     PubMed     Abstract available
     
     
     
152. GUBERT C, Hannan AJ
     Microbial manipulation of memories and minds.
     Brain. 2023;146:4791-4793.
     PubMed    
     
     
     November 2023
153. QUESNEL MJ, Labonte A, Picard C, Zetterberg H, et al
     Insulin-like growth factor binding protein-2 in at-risk adults and autopsy-confirmed Alzheimer brains.
     Brain. 2023 Nov 22:awad398. doi: 10.1093.
     PubMed     Abstract available
     
     
     
154. SILVA-RODRIGUEZ J, Labrador-Espinosa MA, Moscoso A, Scholl M, et al
     Characteristics of amnestic patients with hypometabolism patterns suggestive of Lewy body pathology.
     Brain. 2023;146:4520-4531.
     PubMed     Abstract available
     
     
     
155. HAMPEL H, Elhage A, Cho M, Apostolova LG, et al
     Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics.
     Brain. 2023;146:4414-4424.
     PubMed     Abstract available
     
     
     
156. RAMANAN VK, Gebre RK, Graff-Radford J, Hofrenning E, et al
     Genetic risk scores enhance the diagnostic value of plasma biomarkers of brain amyloidosis.
     Brain. 2023;146:4508-4519.
     PubMed     Abstract available
     
     
     October 2023
157. GRABRUCKER S, Marizzoni M, Silajdzic E, Lopizzo N, et al
     Microbiota from Alzheimer's patients induce deficits in cognition and hippocampal neurogenesis.
     Brain. 2023 Oct 18:awad303. doi: 10.1093.
     PubMed     Abstract available
     
     
     
158. TUNOLD JA, Tan MMX, Koga S, Geut H, et al
     Lysosomal polygenic risk is associated with the severity of neuropathology in Lewy body disease.
     Brain. 2023;146:4077-4087.
     PubMed     Abstract available
     
     
     
159. KEPP KP, Robakis NK, Hoilund-Carlsen PF, Sensi SL, et al
     The amyloid cascade hypothesis: an updated critical review.
     Brain. 2023;146:3969-3990.
     PubMed     Abstract available
     
     
     
160. DU F, Yu Q, Swerdlow RH, Waites CL, et al
     Glucocorticoid-driven mitochondrial damage stimulates Tau pathology.
     Brain. 2023;146:4378-4394.
     PubMed     Abstract available
     
     
     September 2023
161. COOMANS EM, van Westen D, Pichet Binette A, Strandberg O, et al
     Interactions between vascular burden and amyloid-beta pathology on trajectories of tau accumulation.
     Brain. 2023 Sep 18:awad317. doi: 10.1093.
     PubMed     Abstract available
     
     
     
162. HARDY J, Mummery C
     Reply: Lecanemab: turning point, or status quo? An ethics perspective.
     Brain. 2023;146:e73.
     PubMed    
     
     
     
163. BOCANCEA DI, Svenningsson AL, van Loenhoud AC, Groot C, et al
     Determinants of cognitive and brain resilience to tau pathology: a longitudinal analysis.
     Brain. 2023;146:3719-3734.
     PubMed     Abstract available
     
     
     
164. DALY T
     Lecanemab: turning point, or status quo? An ethics perspective.
     Brain. 2023;146:e71-e72.
     PubMed    
     
     
     
165. COOMANS EM, Tomassen J, Ossenkoppele R, Tijms BM, et al
     Genetically identical twin-pair difference models support the amyloid cascade hypothesis.
     Brain. 2023;146:3735-3746.
     PubMed     Abstract available
     
     
     August 2023
166. KERAMIDIS I, McAllister BB, Bourbonnais J, Wang F, et al
     Restoring neuronal chloride extrusion reverses cognitive decline linked to Alzheimer's disease mutations.
     Brain. 2023 Aug 8:awad250. doi: 10.1093.
     PubMed     Abstract available
     
     
     
167. JUNG Y, Damoiseaux JS
     The potential of blood neurofilament light as a marker of neurodegeneration for Alzheimer's disease.
     Brain. 2023 Aug 4:awad267. doi: 10.1093.
     PubMed     Abstract available
     
     
     
168. WUESTEFELD A, Pichet Binette A, Berron D, Spotorno N, et al
     Age-related and amyloid-beta-independent tau deposition and its downstream effects.
     Brain. 2023;146:3192-3205.
     PubMed     Abstract available
     
     
     
169. RAHAYEL S, Tremblay C, Vo A, Misic B, et al
     Mitochondrial function-associated genes underlie cortical atrophy in prodromal synucleinopathies.
     Brain. 2023;146:3301-3318.
     PubMed     Abstract available
     
     
     
170. MCMILLAN PJ, Benbow SJ, Uhrich R, Saxton A, et al
     Tau-RNA complexes inhibit microtubule polymerization and drive disease-relevant conformation change.
     Brain. 2023;146:3206-3220.
     PubMed     Abstract available
     
     
     July 2023
171. GARCIA AM, de Leon J, Tee BL, Blasi DE, et al
     Speech and language markers of neurodegeneration: a call for global equity.
     Brain. 2023 Jul 27:awad253. doi: 10.1093.
     PubMed     Abstract available
     
     
     
172. AKSMAN LM, Oxtoby NP, Scelsi MA, Wijeratne PA, et al
     A data-driven study of Alzheimer's disease related amyloid and tau pathology progression.
     Brain. 2023 Jul 11:awad232. doi: 10.1093.
     PubMed     Abstract available
     
     
     
173. YOUNG AL, Vogel JW, Robinson JL, McMillan CT, et al
     Data-driven neuropathological staging and subtyping of TDP-43 proteinopathies.
     Brain. 2023;146:2975-2988.
     PubMed     Abstract available
     
     
     June 2023
174. 
     Correction to: Brain-derived tau: a novel blood-based biomarker for Alzheimer's disease-type neurodegeneration.
     Brain. 2023 Jun 27:awad208. doi: 10.1093.
     PubMed    
     
     
     
175. VAN DER ENDE EL, In 't Veld SGJG, Hanskamp I, van der Lee S, et al
     CSF proteomics in autosomal dominant Alzheimer's disease highlights parallels with sporadic disease.
     Brain. 2023 Jun 22:awad213. doi: 10.1093.
     PubMed     Abstract available
     
     
     
176. BANERJEE G, Collinge J, Fox NC, Lashley T, et al
     Clinical considerations in early-onset cerebral amyloid angiopathy.
     Brain. 2023 Jun 6:awad193. doi: 10.1093.
     PubMed     Abstract available
     
     
     
177. SCHOONHOVEN DN, Coomans EM, Millan AP, van Nifterick AM, et al
     Tau protein spreads through functionally connected neurons in Alzheimer's disease: a combined MEG/PET study.
     Brain. 2023 Jun 5:awad189. doi: 10.1093.
     PubMed     Abstract available
     
     
     
178. 
     Correction: The most valuable player or the tombstone: is tau the correct target to treat Alzheimer's disease?
     Brain. 2023 Jun 1:awad176. doi: 10.1093.
     PubMed    
     
     
     
179. EDWARDS HM, Wallace CE, Gardiner WD, Doherty BM, et al
     Sex-dependent effects of acute stress on amyloid-beta in male and female mice.
     Brain. 2023;146:2268-2274.
     PubMed     Abstract available
     
     
     
180. ROBINSON JL, Xie SX, Baer DR, Suh E, et al
     Pathological combinations in neurodegenerative disease are heterogeneous and disease-associated.
     Brain. 2023;146:2557-2569.
     PubMed     Abstract available
     
     
     May 2023
181. ZHU M, Xiao B, Xue T, Qin S, et al
     Cdc42GAP deficiency contributes to the Alzheimer's disease phenotype.
     Brain. 2023 May 31:awad184. doi: 10.1093.
     PubMed     Abstract available
     
     
     
182. DAS V, Hajduch M
     Randomizing for Alzheimer's disease drug trials should consider the cancer history of participants.
     Brain. 2023 May 27:awad177. doi: 10.1093.
     PubMed    
     
     
     
183. HARDY J, Mummery C
     Reply: Unblinding in the lecanemab trial in Alzheimer's disease.
     Brain. 2023 May 23:awad201. doi: 10.1093.
     PubMed    
     
     
     
184. VAN GOOL WA
     Unblinding in the lecanemab trial in Alzheimer's disease.
     Brain. 2023 May 18:awad171. doi: 10.1093.
     PubMed    
     
     
     
185. KORETSKY MJ, Alvarado C, Makarious MB, Vitale D, et al
     Genetic risk factor clustering within and across neurodegenerative diseases.
     Brain. 2023 May 16:awad161. doi: 10.1093.
     PubMed     Abstract available
     
     
     
186. JIANG J, Johnson JCS, Requena-Komuro MC, Benhamou E, et al
     Comprehension of acoustically degraded speech in Alzheimer's disease and primary progressive aphasia.
     Brain. 2023 May 15:awad163. doi: 10.1093.
     PubMed     Abstract available
     
     
     
187. YOUNES K, Sha SJ
     The MVP or the tombstone: is tau the correct target to treat Alzheimer's disease?
     Brain. 2023 May 8:awad151. doi: 10.1093.
     PubMed    
     
     
     April 2023
188. GOSSYE H, Van Mossevelde S, Sieben A, Bjerke M, et al
     Patients carrying the mutation p.R406W in MAPT present with non-conforming phenotypic spectrum.
     Brain. 2023;146:1624-1636.
     PubMed     Abstract available
     
     
     
189. PONNUSAMY M, Wang S, Yuksel M, Hansen MT, et al
     Loss of forebrain BIN1 attenuates hippocampal pathology and neuroinflammation in a tauopathy model.
     Brain. 2023;146:1561-1579.
     PubMed     Abstract available
     
     
     
190. NAM MH, Ko HY, Kim D, Lee S, et al
     Visualizing reactive astrocyte-neuron interaction in Alzheimer's disease using 11C-acetate and 18F-FDG.
     Brain. 2023 Apr 17:awad037. doi: 10.1093.
     PubMed     Abstract available
     
     
     
191. MATTSSON-CARLGREN N, Palmqvist S
     The emerging era of staging Alzheimer's disease pathology using plasma biomarkers.
     Brain. 2023 Apr 6:awad112. doi: 10.1093.
     PubMed    
     
     
     March 2023
192. 
     Correction to: Blood-brain barrier opening of the default mode network in Alzheimer's disease with magnetic resonance-guided focused ultrasound.
     Brain. 2023 Mar 22:awad082. doi: 10.1093.
     PubMed    
     
     
     
193. DONADIO V, Incensi A, Rizzo G, Westermark GT, et al
     Phosphorylated alpha-synuclein in skin Schwann cells: a new biomarker for multiple system atrophy.
     Brain. 2023;146:1065-1074.
     PubMed     Abstract available
     
     
     
194. GREVE HJ, Dunbar AL, Lombo CG, Ahmed C, et al
     The bidirectional lung brain-axis of amyloid-beta pathology: ozone dysregulates the peri-plaque microenvironment.
     Brain. 2023;146:991-1005.
     PubMed     Abstract available
     
     
     February 2023
195. JACK CR, Wiste HJ, Algeciras-Schimnich A, Figdore DJ, et al
     Predicting amyloid PET and tau PET stages with plasma biomarkers.
     Brain. 2023 Feb 15:awad042. doi: 10.1093.
     PubMed     Abstract available
     
     
     September 2022
196. GROOT C, Smith R, Stomrud E, Binette AP, et al
     Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals.
     Brain. 2022 Sep 9. pii: 6695020. doi: 10.1093.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Alzheimer's Disease is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum